

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTADEG1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS	4	APR 07	STN is raising the limits on saved answers
NEWS	5	APR 24	CA/CAPplus now has more comprehensive patent assignee information
NEWS	6	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS	7	APR 28	CAS patent authority coverage expanded
NEWS	8	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS	9	APR 28	Limits doubled for structure searching in CAS REGISTRY
NEWS	10	MAY 08	STN Express, Version 8.4, now available
NEWS	11	MAY 11	STN on the Web enhanced
NEWS	12	MAY 11	BEILSTEIN substance information now available on STN Easy
NEWS	13	MAY 14	DGENE, PCTGEN and USGENE enhanced with increased limits for exact sequence match searches and introduction of free HIT display format
NEWS	14	MAY 15	INPADOCDB and INPAFAMDB enhanced with Chinese legal status data
NEWS	15	MAY 28	CAS databases on STN enhanced with NANO super role in records back to 1992
NEWS	16	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS	17	JUN 26	NUTRACEUT and PHARMAML no longer updated
NEWS	18	JUN 29	IMSCOPROFILE now reloaded monthly
NEWS	19	JUN 29	EPFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields
NEWS	20	JUL 09	PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields
NEWS	21	JUL 14	USGENE enhances coverage of patent sequence location (PSL) data
NEWS	22	JUL 14	CA/CAPplus to be enhanced with new citing references features

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:42:07 ON 15 JUL 2009

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 09:42:31 ON 15 JUL 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 JUL 2009 HIGHEST RN 1162342-48-4

DICTIONARY FILE UPDATES: 13 JUL 2009 HIGHEST RN 1162342-48-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10-509279genAx.str



```

chain nodes :
19 21 22 23 25
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
7-10 9-19 13-21 21-22 22-25 22-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15
exact/norm bonds :
5-7 6-9 7-8 8-9 9-19 10-11 10-15 11-12 12-13 13-14 13-21 14-15 22-25
22-23
exact bonds :
7-10 21-22
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```

G1:C,N

G2:C,H

G3:C,H,O,Cl,Br,F,I

G4:O,N

G5:H,Cy

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 19:CLASS 21:Atom 22:CLASS 23:CLASS
25:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS



L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10-509279genBx.str



chain nodes :

19 21 22 23 25

```

ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15
chain bonds :
7-10  9-19  13-21  21-22  22-25  22-23
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-9  7-8  8-9  10-11  10-15  11-12  12-13  13-14
14-15
exact/norm bonds :
5-7  6-9  7-8  8-9  9-19  10-11  10-15  11-12  12-13  13-14  13-21  14-15  22-25
22-23
exact bonds :
7-10  21-22
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6

```

G1:C,N

G2:C,H

G3:C,H,O,Cl,Br,F,I

G4:O,N

G5:H,Cy

```

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 19:CLASS 21:Atom 22:CLASS 23:CLASS
25:CLASS

```

L2 STRUCTURE UPLOADED

=> d 12

L2 HAS NO ANSWERS



L2 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10-509279genCx.str



```

chain nodes :
19 21 22 23 25
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
7-10 9-19 13-21 21-22 22-25 22-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15
exact/norm bonds :
5-7 6-9 7-8 8-9 9-19 10-11 10-15 11-12 12-13 13-14 13-21 14-15 22-25
22-23
exact bonds :
7-10 21-22
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```

G1:C,N

G2:C,H

G3:C,H,O,Cl,Br,F,I

G4:O,N

G5:H,Cy

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 19:CLASS 21:Atom 22:CLASS 23:CLASS
25:CLASS

L3 STRUCTURE UPLOADED

=> d 13

L3 HAS NO ANSWERS



L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10-509279genDx.str



chain nodes :

19 21 22 23 25

```

ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15
chain bonds :
7-10  9-19  13-21  21-22  22-25  22-23
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-9  7-8  8-9  10-11  10-15  11-12  12-13  13-14
14-15
exact/norm bonds :
5-7  6-9  7-8  8-9  9-19  10-11  10-15  11-12  12-13  13-14  13-21  14-15  22-25
22-23
exact bonds :
7-10  21-22
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6

```

G1:C,N

G2:C,H

G3:C,H,O,Cl,Br,F,I

G4:O,N

G5:H,Cy

```

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 19:CLASS 21:Atom 22:CLASS 23:CLASS
25:CLASS

```

L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS

L4 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full

FULL SEARCH INITIATED 09:44:23 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3767 TO ITERATE

100.0% PROCESSED 3767 ITERATIONS

8 ANSWERS

SEARCH TIME: 00.00.01

L5 8 SEA SSS FUL L1

=> s l2 sss full

FULL SEARCH INITIATED 09:44:36 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 20284 TO ITERATE

100.0% PROCESSED 20284 ITERATIONS

4 ANSWERS

SEARCH TIME: 00.00.02

L6 4 SEA SSS FUL L2

=> s 13 sss full
FULL SEARCH INITIATED 09:44:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6401 TO ITERATE

100.0% PROCESSED 6401 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.01

L7 9 SEA SSS FUL L3

=> s 14 sss full
FULL SEARCH INITIATED 09:45:08 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4550 TO ITERATE

100.0% PROCESSED 4550 ITERATIONS 25 ANSWERS
SEARCH TIME: 00.00.02

L8 25 SEA SSS FUL L4

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	744.00	744.22

FILE 'CAPLUS' ENTERED AT 09:45:37 ON 15 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Jul 2009 VOL 151 ISS 3
FILE LAST UPDATED: 14 Jul 2009 (20090714/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:


<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.


The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases will soon be updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 22.

=> s 15

L9 5 L5
 => s 16
 L10 2 L6
 => s 17
 L11 6 L7
 => s 18
 L12 10 L8
 => s 19 or 110 or 111 or 112
 L13 15 L9 OR L10 OR L11 OR L12
 => s 113 and pd<20020700
 22800249 PD<20020700
 (PD<20020700)
 L14 4 L13 AND PD<20020700
 => d 114 1-4 abs ibib hitstr
 L14 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
 GI



I



II

AB Title compds. I [wherein Ar = (un)substituted mono- or bicyclic
 (hetero)aryl; G = (un)substituted alkenediyl or alkanediyl; Q = O, S, or
 (un)substituted N; S, T, Y, and Z = independently N or (un)substituted C;
 R5 and R6 = independently H or alkyl; R7 and R8 = independently H, alkyl,
 alkenyl, alkoxy, alkylthio, halo, carbocyclyl, or heterocyclyl; or R7R8 =
 (un)substituted carbocyclic or heterocyclic ring; R32 = H, (hydroxy)alkyl,
 CN, acyl, carbamoyl, CHO, or alkoxy-carbonyl; n = 0-2; or pharmaceutically
 acceptable salts, amides, esters, or stereoisomers thereof] were prepared as
 cathepsin S inhibitors for the treatment of an allergic condition,
 including an atopic allergic conditions. For example,
 1-methanesulfonylpiperidin-4-one (preparation given) was condensed with

morpholine in the presence of TsOH to give the enamine. Reaction with 4-CF₃C₆H₄COCl, followed by cycloaddn. with H₂NNH₂, gave 5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-1H-pyrazol[4,3-c]pyridine (72%). Alkylation with epichlorohydrin (35%) and addition of 5-chloro-3-piperidin-4-yl-1H-indole (preparation given) afforded II (88%). The latter inhibited recombinant human cathepsin S with IC₅₀ of 0.07 μM.

ACCESSION NUMBER: 2002:184900 CAPLUS
DOCUMENT NUMBER: 136:247577
TITLE: Preparation of
3-phenyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines as
cathepsin S inhibitors for treating allergies
INVENTOR(S): Cai, Hui; Edwards, James P.; Gu, Yin; Karlsson, Lars;
Meduna, Steven P.; Pio, Barbara A.; Sun, Siqun;
Thurmond, Robin L.; Wei, Jianmei
PATENT ASSIGNEE(S): Ortho McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020013	A2	20020314	WO 2001-US27480	20010905 <--
WO 2002020013	A3	20020620		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20020040019	A1	20020404	US 2001-927188	20010810 <--
US 6635633	B2	20031021		
CA 2421510	A1	20020314	CA 2001-2421510	20010905 <--
AU 2001088731	A	20020322	AU 2001-88731	20010905 <--
EP 1315492	A2	20030604	EP 2001-968487	20010905
EP 1315492	B1	20080730		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004508330	T	20040318	JP 2002-524497	20010905
JP 4129391	B2	20080806		
CN 1505509	A	20040616	CN 2001-818504	20010905
CN 1321641	C	20070620		
NZ 524682	A	20041126	NZ 2001-524682	20010905
RU 2259202	C2	20050827	RU 2003-106190	20010905
AU 2001288731	B2	20051215	AU 2001-288731	20010905
AT 402699	T	20080815	AT 2001-968487	20010905
ES 2309088	T3	20081216	ES 2001-968487	20010905
IN 2003KN00264	A	20041009	IN 2003-KN264	20030303
MX 2003001962	A	20040326	MX 2003-1962	20030305
HK 1052881	A1	20090130	HK 2003-105185	20030717
US 20050234102	A1	20051020	US 2005-147923	20050608
US 7265102	B2	20070904		
PRIORITY APPLN. INFO.:			US 2000-230407P	P 20000906
			US 2001-927188	A 20010810
			US 2000-225178P	P 20000814
			WO 2001-US27480	W 20010905

OTHER SOURCE(S): MARPAT 136:247577


IT 400801-80-1P, 4-(1H-Pyrrolo[3,2-c]pyridin-3-yl)-piperidine-1-carboxylic acid tert-butyl ester 400801-83-4P, 4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-piperidine-1-carboxylic acid tert-butyl ester 400801-86-7P, 4-(5-Morpholin-4-yl-1H-pyrrolo[2,3-c]pyridin-3-yl)-piperidine-1-carboxylic acid tert-butyl ester 400801-90-3P, 4-(6-Dimethylamino-1H-pyrrolo[3,2-c]pyridin-3-yl)-piperidine-1-carboxylic acid tert-butyl ester 400801-95-8P, 4-(6-Morpholin-4-yl-1H-pyrrolo[3,2-c]pyridin-3-yl)-piperidine-1-carboxylic acid tert-butyl ester 400801-99-2P, 4-(6-Morpholin-4-yl-5-oxy-1H-pyrrolo[3,2-c]pyridin-3-yl)-piperidine-1-carboxylic acid tert-butyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of phenylpyrazolopyridine antiallergy agents from piperidinones, benzoyl chlorides, and hydrazine)


RN 400801-80-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1H-pyrrolo[3,2-c]pyridin-3-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 400801-83-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 400801-86-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[5-(4-morpholinyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 400801-90-3 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[6-(dimethylamino)-1H-pyrrolo[3,2-c]pyridin-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 400801-95-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[6-(4-morpholinyl)-1H-pyrrolo[3,2-c]pyridin-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 400801-99-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[6-(4-morpholinyl)-5-oxido-1H-pyrrolo[3,2-c]pyridin-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Substituted pyrazoles I, methods of manufacturing them, compns. containing them, and

methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S, are described [W, X, Y, Z = N, (un)substituted CH (0-3 of them may be N; or 1 can be N-oxide when other 3 ≠ N); R = H, alkyl, cyano, hydroxyalkyl, acyl, CHO, alkoxycarbonyl, or (un)substituted carbamoyl; R1, R2 = H, alkyl; R3, R4 = H, alkyl, alkenyl, alkoxy, alkylthio, halo, or 4- to 7-membered carbo- or heterocyclyl; or R3R4 = atoms to form (un)substituted (un)saturated (non)aromatic 5- to 7-membered carbo-

or heterocyclic ring; Ar = (un)substituted mono- or bicyclic (hetero)aryl; n = 0-2; G = (un)substituted C3-6 alkanediyl or alkenediyl (substituents = OH, halo, oxo, aminoalkyl, etc.); Q = O, S, (un)substituted NH; including stereoisomers, pharmaceutically acceptable salts, esters, and amides].

Claimed uses include treatment of lupus, rheumatoid arthritis, and particularly asthma, and inhibition of tissue transplant rejection. Approx. 70 individual compds. I were prepared and/or claimed, with detailed prepn. given for 13 compds. For instance, 6-(morpholin-4-yl)-3-(piperidin-4-yl)-1H-pyrrolo[3,2-c]pyridine (prepared in 5 steps) reacted with the corresponding epoxide (prepared in several steps) to give title compound II, a preferred compound In an assay for inhibition of recombinant human cathepsin S in vitro, II had an IC50 of 0.02 μ M. Compound III is another one of four specifically preferred compds.

ACCESSION NUMBER: 2002:142709 CAPLUS
DOCUMENT NUMBER: 136:200183
TITLE: Substituted and/or fused pyrazoles, particularly indolylpiperidinylpropyl-substituted pyrazolopyridines, useful as cathepsin S inhibitors, and their pharmaceutical compositions and use as immunosuppressants
INVENTOR(S): Cai, Hui; Edwards, James P.; Meduna, Steven P.; Pio, Barbara A.; Wei, Jianmei
PATENT ASSIGNEE(S): Ortho McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014317	A2	20020221	WO 2001-US25180	20010810 <--
WO 2002014317	A3	20020704		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2419550	A1	20020221	CA 2001-2419550	20010810 <--
AU 2001084823	A	20020225	AU 2001-84823	20010810 <--
US 20020040019	A1	20020404	US 2001-927188	20010810 <--
US 6635633	B2	20031021		
EP 1309592	A2	20030514	EP 2001-963912	20010810
EP 1309592	B1	20060426		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004512273	T	20040422	JP 2002-519457	20010810
NZ 524192	A	20050225	NZ 2001-524192	20010810
CN 1255405	C	20060510	CN 2001-817068	20010810
AT 324372	T	20060515	AT 2001-963912	20010810
RU 2278863	C2	20060627	RU 2003-107014	20010810
AU 2001284823	B2	20061130	AU 2001-284823	20010810
ES 2262674	T3	20061201	ES 2001-963912	20010810
CN 1982308	A	20070620	CN 2006-10146464	20010810
MX 2003001420	A	20040126	MX 2003-1420	20030214
IN 2003KN00191	A	20051202	IN 2003-KN191	20030214
ZA 2003002051	A	20040625	ZA 2003-2051	20030313
ZA 2003002056	A	20040702	ZA 2003-2056	20030313
US 20030225062	A1	20031204	US 2003-402694	20030328
US 6936603	B2	20050830		
US 20030225063	A1	20031204	US 2003-402696	20030328

US 6951851	B2	20051004		
US 20030229075	A1	20031211	US 2003-401486	20030328
US 6949540	B2	20050927		
HK 1052705	A1	20060929	HK 2003-105032	20030711
US 20040044027	A1	20040304	US 2003-638032	20030808
US 20050234102	A1	20051020	US 2005-147923	20050608
US 7265102	B2	20070904		

PRIORITY APPLN. INFO.:

US 2000-225178P	P	20000814
US 2001-927188	A	20010810
CN 2001-817066	A3	20010810
US 2001-927324	A	20010810
WO 2001-US25180	W	20010810
US 2003-401486	A1	20030328

OTHER SOURCE(S): MARPAT 136:200183


IT 400801-80-1P, 4-(1H-Pyrrolo[3,2-c]pyridin-3-yl)piperidine-1-carboxylic acid tert-butyl ester 400801-83-4P, 4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)piperidine-1-carboxylic acid tert-butyl ester 400801-86-7P, 4-(5-Morpholin-4-yl-1H-pyrrolo[2,3-c]pyridin-3-yl)piperidine-1-carboxylic acid tert-butyl ester 400801-90-3P, 4-(6-Dimethylamino-1H-pyrrolo[3,2-c]pyridin-3-yl)piperidine-1-carboxylic acid tert-butyl ester 400801-95-8P, 4-(6-Morpholin-4-yl-1H-pyrrolo[3,2-c]pyridin-3-yl)piperidine-1-carboxylic acid tert-butyl ester 400801-99-2P, 4-(6-Morpholin-4-yl-5-oxy-1H-pyrrolo[3,2-c]pyridin-3-yl)piperidine-1-carboxylic acid tert-butyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of indolylpiperidinylpropyl-substituted pyrazolopyridines and analogs as cathepsin S inhibitors)


RN 400801-80-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1H-pyrrolo[3,2-c]pyridin-3-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 400801-83-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 400801-86-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[5-(4-morpholinyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 400801-90-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[6-(dimethylamino)-1H-pyrrolo[3,2-c]pyridin-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 400801-95-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[6-(4-morpholinyl)-1H-pyrrolo[3,2-c]pyridin-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 400801-99-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[6-(4-morpholinyl)-5-oxido-1H-pyrrolo[3,2-c]pyridin-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
GI



I

AB The title compds. [I; AB = C:CH, CHCH₂; R = H, C₁-6 alkyl, PhCH₂, phenylethyl; X = NR₁SO₂R₂, NHC(Q)NR₃R₄, NHC(O)OR₅, NR₁C(O)R₆ (wherein Q = O, S; R₁ = H, C₁-4 alkyl; R₂ = C₁-4 alkyl, (un)substituted Ph; R₃, R₄ = H, C₁-6 alkyl, C₃-6 alkenyl, etc.; R₃R₄ together with the nitrogen atom to which they are attached = pyrrolidine, piperidine, (un)substituted piperazine, etc.; R₅ = C₁-6 alkyl, C₃-6 alkenyl, (un)substituted Ph, etc.; R₆ = C₁-10 alkyl, C₂-10 alkenyl, C₂-10 alkynyl, etc.)], useful in treating conditions associated with 5-HT_{1F} activation such as migraine or chronic pain, and for the prevention or inhibition of neuronal protein extravasation, were prepared and formulated. Thus, reaction of 5-amino-3-(1-methylpiperidin-4-yl)pyrrolo[3,2-b]pyridine (preparation described) with cyclopropanecarbonyl chloride in pyridine afforded 56% I [AB = CHCH₂; R = Me; X = N-(cyclopropanecarbonyl)amino]. Compds. I are effective at 0.1-15 mg/kg/day.

ACCESSION NUMBER: 1998:650038 CAPLUS

DOCUMENT NUMBER: 129:275837

ORIGINAL REFERENCE NO.: 129:56245a, 56248a

TITLE: Preparation of pyrrolo[3,2-b]pyridines as 5-HT_{1F} agonists

INVENTOR(S): Filla, Sandra Ann; Johnson, Kirk W.; Phebus, Lee A.; Schaus, John Mehnert

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: U.S., 32 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5817671	A	19981006	US 1997-969851	19971114 <--
US 5919936	A	19990706	US 1998-112560	19980709 <--
US 5998622	A	19991207	US 1998-112562	19980709 <--
PRIORITY APPLN. INFO.:			US 1997-969851	A3 19971114


OTHER SOURCE(S): MARPAT 129:275837

IT 207849-70-5


RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrrolo[3,2-b]pyridines as 5-HT_{1F} agonists)

RN 207849-70-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(5-amino-1H-pyrrolo[3,2-b]pyridin-3-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




IT 207849-83-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrrolo[3,2-b]pyridines as 5-HT1F agonists)
 RN 207849-83-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[5-[[2-propen-1-yloxy)carbonyl]amino]-1H-
 pyrrolo[3,2-b]pyridin-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
 GI



AB The title compds. [I; AB = C:CH, CHCH₂; R = H, C₁-6 alkyl, PhCH₂,
 PhCH₂CH₂; X = NR₁SO₂R₂, NHC(Q)NR₃R₄, NHC(O)OR₅, NR₁C(O)R₆ (wherein Q = O,
 S; R₁ = H, C₁-4 alkyl; R₂ = C₁-4 alkyl, (un)substituted Ph; R₃, R₄ = H,
 C₁-6 alkyl, C₃-6 alkenyl, etc.; NR₃R₄ = pyrrolidino, piperidino,
 morpholino, etc.; R₅ = C₁-6 alkyl, C₃-6 alkenyl, (un)substituted Ph, etc.;
 R₆ = (un)substituted C₁-10 alkyl, C₂-10 alkenyl, C₂-10 alkynyl, etc.)],
 5-HT_{1F} agonists useful in the treatment of migraine, chronic pain, and for
 the prevention or inhibition of neuronal protein extravasation, were
 prepared Thus, reaction of 5-amino-3-(1-methylpiperidin-4-yl)pyrrolo[3,2-
 b]pyridine (preparation described) with cyclopropylcarbonyl chloride in


pyridine afforded 56% I [AB = CHCH₂; R = Me; X = N-(cyclopropylcarbonyl)amino]. Compds. I are effective at 0.1-15 mg/kg/day.

ACCESSION NUMBER: 1998:344364 CAPLUS
 DOCUMENT NUMBER: 129:27901
 ORIGINAL REFERENCE NO.: 129:5947a,5950a
 TITLE: Preparation of pyrrolo[3,2-b]pyridines as 5-HT_{1F} agonists
 INVENTOR(S): Filla, Sandra Ann; Schaus, John Mehnert; Phebus, Lee Alan; Johnson, Kirk Willis
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: Eur. Pat. Appl., 50 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 842934	A1	19980520	EP 1997-309106	19971112 <--
EP 842934	B1	20031029		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
ZA 9709961	A	19990505	ZA 1997-9961	19971105 <--
IN 1997CA02126	A	20050311	IN 1997-CA2126	19971111
EP 1082958	A2	20010314	EP 2000-203526	19971112 <--
EP 1082958	A3	20021211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
AT 253063	T	20031115	AT 1997-309106	19971112
ES 2210463	T3	20040701	ES 1997-309106	19971112
CA 2271272	A1	19980522	CA 1997-2271272	19971113 <--
WO 9820875	A1	19980522	WO 1997-US20630	19971113 <--
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9854352	A	19980603	AU 1998-54352	19971113 <--
JP 2001503774	T	20010321	JP 1998-522777	19971113 <--
NO 9901974	A	19990426	NO 1999-1974	19990426 <--
PRIORITY APPLN. INFO.:			US 1996-30950P	P 19961115
			EP 1997-309106	A3 19971112
			WO 1997-US20630	W 19971113


OTHER SOURCE(S): MARPAT 129:27901

IT 207849-70-5P 207849-83-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrrolo[3,2-b]pyridines as 5-HT_{1F} agonists)
 RN 207849-70-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(5-amino-1H-pyrrolo[3,2-b]pyridin-3-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 207849-83-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[5-[[(2-propen-1-yloxy)carbonyl]amino]-1H-pyrrolo[3,2-b]pyridin-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

=>

=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 10:23:11 ON 15 JUL 2009